A Phase 1 interventional study of Icovamenib and Icovamenib HPMC in Healthy Volunteer, sponsored by Biomea Fusion Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Biomea Fusion Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A phase 1 open-label, randomized, crossover food effect and formulation assessment for icovamenib capsule in healthy volunteers.
This is a phase 1, open-label, randomized, single dose, up to 7-way crossover study. It is planned to enroll 60 healthy male and female subjects. Subjects will be randomized to receive one of 5 sequences, with N=12 per sequence. Subjects will be dosed in a single residency period. This study is designed to evaluate the effect of meal time and fat content of food on the PK and safety of the icovamenib capsule and the icovamenib hydroxypropyl methylcellulose (HPMC) capsule formulation.
Biomea Fusion Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
and Compliance
Exclusion Criteria:
Medical/Surgical History and Mental Health
History of stomach or intestinal surgery or resection (except appendectomy, hernia and/or cholecystectomy).
Diagnostic assessments.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A - icovamenib capsule 100mg in fasted state
Drug: Icovamenib
B - icovamenib capsule 100mg in the fed state (0.5 h after initiation of low-fat breakfast)
Drug: Icovamenib
C - icovamenib capsule 100mg in the fed state (1 h after initiation of a low-fat breakfast)
Drug: Icovamenib
D - icovamenib capsule 100mg in the fed state (0.5 h after initiation of a high-fat breakfast)
Drug: Icovamenib
E - icovamenib capsule 100mg in the fed state (1 h after initiation of a high-fat breakfast)
Drug: Icovamenib
F - icovamenib HPMC capsule 100mg in the fed state (0.5 h after initiation of a high-fat breakfast)
Drug: Icovamenib HPMC
G - icovamenib HPMC capsule 100mg in the fed state (1h after initiation of a high-fat breakfast)
Drug: Icovamenib HPMC
H - icovamenib HPMC capsule 100mg in the fed state (0.5 h after initiation of a low-fat breakfast)
Drug: Icovamenib HPMC
I - icovamenib HPMC capsule 100mg in the fed state (1 h after initiation of a low-fat breakfast)
Drug: Icovamenib HPMC
Investigational Product
Also known as: BMF-219
Investigational Product
Also known as: BMF-219 HPMC
Evaluate food effect and PK profile of icovamenib capsule formulation in fed and fasted states
Tmax
Time frame: Every other day for a max of 2 weeks
Evaluate food effect and PK profile of icovamenib capsule formulation in fed and fasted states
Cmax
Time frame: Every other day for a max of 2 weeks
Evaluate food effect and PK profile of icovamenib capsule formulation in fed and fasted states
AUC (0-last)
Time frame: Every other day for a max of 2 weeks
Evaluate food effect and PK profile of icovamenib capsule formulation in fed and fasted states
AUC (0-inf)
Time frame: Every other day for a max of 2 weeks
Evaluate food effect and PK profile of icovamenib capsule formulation in fed and fasted states
T1/2
Time frame: Every other day for a max of 2 weeks
Evaluate food effect and PK profile of icovamenib capsule formulation in fed and fasted states
MRT (0-inf)
Time frame: Every other day for a max of 2 weeks
Evaluate food effect and PK profile of icovamenib capsule formulation in fed and fasted states
Tlag
Time frame: Time Frame: Every other day for a max of 2 weeks
Evaluate food effect and PK profile of icovamenib HPMC capsule formulation in fed states
Tmax
Time frame: Every other day for a max of 2 weeks
Evaluate food effect and PK profile of icovamenib HPMC capsule formulation in fed states
Cmax
Time frame: Every other day for a max of 2 weeks
Evaluate food effect and PK profile of icovamenib HPMC capsule formulation in fed states
AUC (0-last)
Time frame: Every other day for a max of 2 weeks
Evaluate food effect and PK profile of icovamenib HPMC capsule formulation in fed states
AUC (0-inf)
Time frame: Every other day for a max of 2 weeks
Evaluate food effect and PK profile of icovamenib HPMC capsule formulation in fed states
T1/2
Time frame: Every other day for a max of 2 weeks
Evaluate food effect and PK profile of icovamenib HPMC capsule formulation in fed states
MRT(0-inf)
Time frame: Every other day for a max of 2 weeks
Evaluate food effect and PK profile of icovamenib HPMC capsule formulation in fed states
Tlag
Time frame: Every other day for a max of 2 weeks
Evaluate food effect and PK profile of icovamenib HPMC capsule formulation in fed states
Clast
Time frame: Every other day for a max of 2 weeks
Assess safety and tolerability of icovamenib as capsule and HPMC capsule
Incidence of adverse events (AEs)
Time frame: Every other day for a max of 2 weeks
Assess safety and tolerability in vital signs of icovamenib as capsule and HPMC capsule
Blood pressure (mmHg)
Time frame: Every other day for a max of 2 weeks
Assess safety and tolerability in vital signs of icovamenib as capsule and HPMC capsule
Heart rate (beats per minute)
Time frame: Every other day for a max of 2 weeks
Assess safety and tolerability in ECG of icovamenib as capsule and HPMC capsule
Heart rate (beats per minute)
Time frame: Every other day for a max of 2 weeks
Assess safety and tolerability in ECG of icovamenib as capsule and HPMC capsule
PR interval (ms)
Time frame: Every other day for a max of 2 weeks
Assess safety and tolerability in ECG of icovamenib as capsule and HPMC capsule
QRS interval (ms)
Time frame: Every other day for a max of 2 weeks
Assess safety and tolerability in ECG of icovamenib as capsule and HPMC capsule
QT interval (ms)
Time frame: Every other day for a max of 2 weeks
Assess safety and tolerability in ECG of icovamenib as capsule and HPMC capsule
QTcF interval (ms)
Time frame: Every other day for a max of 2 weeks
Number of participants with abnormal physical examination
General appearance
Time frame: Every other day for a max of 2 weeks
Number of participants with abnormal laboratory test findings
Clinical chemistry such as alanine aminotransferase (U/L), aspartate aminotransferase (U/L), alkaline phosphatase (U/L), total bilirubin (mg/dL)
Time frame: Every other day for a max of 2 weeks
Number of participants with abnormal laboratory test findings
Hematology such as red blood cell (x 10\^6/uL), white blood cell (x 10\^3/uL), and platelet count (x 10\^3/uL)
Time frame: Every other day for a max of 2 weeks
Number of participants with abnormal laboratory test findings
Coagulation such as fibrinogen (mg/dL), prothrombin time (s), international normalized ratio (no units)
Time frame: Every other day for a max of 2 weeks
Number of participants with abnormal urine test findings
Urinalysis such as color (no units), appearance (no units), pH (pH)
Time frame: Every other day for a max of 2 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Jan 2026, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Icovamenib
Biomea Fusion Inc.